Please login to the form below

Not currently logged in
Email:
Password:

Teva sues Apotex to block generic Coreg

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Israel-headquartered Teva Pharmaceutical has sued Canada-based Apotex to prevent the generic rival from selling a copy of GlaxoSmithKline's (GSK) antihypertensive drug, Coreg (carvedilol).

Apotex, Teva and other generic-drug makers won FDA approval to sell the generic version on 5 September 2007. Teva says that it owns four patents which cover various forms and processes to make carvedilol.

To sell carvedilol, says Teva, Apotex might have to purchase the compound made using the patented process. Apotex has not supplied the necessary data required to rule whether the generic uses patented processes or not. Teva has filed for a court order to prevent patent infringement by Apotex.

For H1 FY07, Coreg posted sales of USD 854m and analysts say that the annual generic market for carvedilol could be worth as much as USD 50m.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics